secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-06-29T21:19:24+00:00
Accession:  0001213900-26-073213
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics appoints John P. Sharp interim CFO; board member resigns, classes realigned
--------------------------------------------------------------------------------

- John P. Sharp appointed Interim CFO effective June 25, 2026, replacing Quang X. Pham.
- Compensation: $455/hour, up to 24 hours/week via Lohman & Associates Master Services Agreement.
- Steven Zelenkofske resigns from board effective June 30, 2026; no disagreement cited.
- Board realigned: Glynn Wilson moved from Class I to Class III director to balance classes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026073213/0001213900-26-073213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026073213/ea0296328-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-073213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer